Insights
Search Results
Client Highlights
8.13.25
Firm Advises SetPoint Medical on $140 Million Private Financing
On August 11, 2025, SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, announced it has raised $140 million in private financing, including $25 million in the second tranche of its Series C financing and $115 million in Series D financing, co-led by Elevage Medical Technologies and Ally Bridge Group. Wilson Sonsini Goodrich & Rosati advised SetPoint Medical on the transaction.
Client Highlights
8.07.25
Wilson Sonsini Advises Apreo Health on Oversubscribed $130 Million Series B
On August 7, 2025, Apreo Health, a clinical-stage medical device company developing a novel treatment for severe emphysema, announced the closing of an oversubscribed $130 million Series B financing round. The financing was co-led by new investors Bain Capital Life Sciences and Norwest, with participation from new investors F-Prime and Intuitive Ventures. Returning investors Lightstone Ventures and Santé Ventures also participated in the round. Wilson Sonsini Goodrich & Rosati advised Apreo Health on the transaction.
Client Highlights
11.01.21
Wilson Sonsini Advises Roblox on Senior Notes Offering
On October 27, 2021, Roblox announced the pricing of $1.0 billion aggregate principal amount of its 3.875 percent senior notes due 2030. The notes were offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The sale of the notes closed on October 29, 2021. Wilson Sonsini Goodrich & Rosati represented Roblox in the transaction.
Client Highlights
7.21.21
Wilson Sonsini Advises Saranas on $12.8 Million Series B Investment
On July 19, 2021, Houston, Texas-based Saranas announced a $12.8 million Series B investment led by Baird Capital. Austin-based S3 Ventures also joined the funding round. Wilson Sonsini Goodrich & Rosati represented Saranas in the transaction.
Client Highlights
3.15.21
Wilson Sonsini Advises Roblox in Direct Listing on NYSE
On March 10, 2021, Roblox Corporation, an online human co-experience platform with millions of immersive digital experiences, commenced trading of its Class A common stock in a direct listing on the New York Stock Exchange symbol “RBLX.” In its debut on the NYSE, Roblox’s stock closed at $69.50 on March 10, giving the company a market cap of $38 billion. Wilson Sonsini Goodrich & Rosati advised Roblox in the transaction.
Client Highlights
6.25.20
Wilson Sonsini Advises Derivative Path in $35 Million Fundraise
On June 24, 2020, Derivative Path, Inc. (DPI), a leading capital markets financial technology and services company, announced that it has secured $35 million in growth equity funding from FTV Capital, a successful investor in innovative, high-growth companies within the enterprise technology and services, financial services, and payments and transaction processing sectors. The investment is DPI’s first outside institutional round and will be used to expand its product offerings and help accelerate the company’s client-centric growth with financial institutions, end users, and buy-side clients using DPI’s interest rate derivatives and foreign exchange platform. Wilson Sonsini Goodrich & Rosati represented Derivative Path in the transaction.
Client Highlights
4.16.20
Firm Advises Kindred Biosciences in $43 Million Sale of Mirataz®
On April 15, 2020, Kindred Biosciences (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, announced that it has completed the sale of Mirataz® (mirtazapine transdermal ointment), a topical medication for use in cats, to Dechra Pharmaceuticals for an upfront payment of $43 million and royalties on worldwide sales. Wilson Sonsini Goodrich & Rosati represented Kindred Biosciences in the transaction.
Client Highlights
3.03.20
Roblox Raises $150 Million Series G
On February 26, 2020, Roblox announced it raised $150 million and launched a tender offer to buy up to $350 million of common and preferred shares. The financing round was led by venture-capital giant Andreessen Horowitz. New investors included Temasek and Tencent Holdings Limited. Existing investors including Altos Ventures, Meritech Capital, and Tiger Global Management also participated in the funding round. Wilson Sonsini Goodrich & Rosati represented Roblox in the transaction; former Wilson Sonsini partner Mark Reinstra, who is now serving as general counsel of Roblox, was also involved in the financing.
Client Highlights
7.23.18
Establishment Labs Announces Closing of Initial Public Offering
On July 23, 2018, Establishment Labs, a global medical technology company focused on breast aesthetics and reconstruction technologies, announced the closing of its initial public offering of 4,272,568 common shares at a public offering price of $18.00 per share, which includes the full exercise of the underwriters' option to purchase 557,291 additional shares. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Establishment Labs, were approximately $76.9 million. The shares began trading on the Nasdaq Capital Market under the ticker symbol "ESTA" on July 19.
Client Highlights
1.24.18
Millipede Secures Investment from and Enters into Acquisition Option Agreement with Boston Scientific
On January 24, 2018, medical device manufacturer Boston Scientific announced that it has closed an investment and has entered into an acquisition option agreement with Millipede, a privately held company that has developed a system for the treatment of severe mitral regurgitation. Wilson Sonsini Goodrich & Rosati is representing Millipede in the transactions.
Alerts
10.19.17
SEC Proposes Modernization and Simplification of Regulation S-K
On October 11, 2017, the Securities and Exchange Commission (SEC) voted unanimously to propose amendments to modernize and simplify certain disclosure requirements in Regulation S-K applicable to public companies, investment advisers, and investment companies. The vote represents the latest step by the SEC to implement its mandate under the Fixing America's Surface Transportation (FAST) Act, which was signed into law in December 2015. The proposed amendments are intended to "further scale or eliminate requirements... [in order] to reduce the burden on emerging growth companies, accelerated filers, smaller reporting companies, and other smaller issuers, while still providing all material information to investors" and to "eliminate provisions... that are duplicative, overlapping, outdated, or unnecessary."1